Perspectives in Clinical Research

ORIGINAL ARTICLE
Year
: 2016  |  Volume : 7  |  Issue : 1  |  Page : 45--50

Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial


Brij Mohan Gupta1, Samir H Zargar1, Manu Arora2, Vishal R Tandon1 
1 Department of Pharmacology and Therapeutics, Government Medical College, Jammu, Jammu and Kashmir, India
2 Department of Psychiatry, Government Medical College, Jammu, Jammu and Kashmir, India

Correspondence Address:
Vishal R Tandon
Department of Pharmacology, Government Medical College, Jammu - 180 001, Jammu and Kashmir
India

Aim and Objective: To compare efficacy and safety of escitalopram with desvenlafaxine in the treatment of major depression.Materials and Methods: A total of 60 patients of depression were randomized into two groups after meeting inclusion criterion. In the first 3 weeks, escitalopram 10 mg/day was given and then 20 mg/day for the next 3 weeks in group 1 (n = 30). Desvenlafaxine in the first 3 weeks was given 50 mg/day and 100 mg/day for the next 3 weeks in group 2 (n = 30). The parameters evaluated during the study were efficacy assessments byHamilton Scale of Rating Depression (HAM-D), Hamilton Rating Scale of Anxiety (HAM-A), and Clinical Global Impression (CGI). Safety assessments were done by UKU-scale. Results: Escitalopram and desvenlafaxine significantly (P < 0.001), reduced HAM-D, HAM-A, and CGI scores from their respective base lines. However, on comparison failed show any statistical difference at 3 and 6 weeks of treatment. Escitalopram and desvenlafaxine were both found to be safe and well-tolerated and there was not much difference between the two groups as evident from UKU Scale and their effect on various biochemical parameters. Conclusion: The present study demonstrated similar efficacy and safety in reducing depression and anxiety with both escitalopram and desvenlafaxine, but clinical superiority of one drug over the other cannot be concluded due to limitations of the small sample size.


How to cite this article:
Gupta BM, Zargar SH, Arora M, Tandon VR. Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial.Perspect Clin Res 2016;7:45-50


How to cite this URL:
Gupta BM, Zargar SH, Arora M, Tandon VR. Efficacy and safety of escitalopram versus desvenlafaxine in the treatment of major depression: A preliminary 1-year prospective randomized open label comparative trial. Perspect Clin Res [serial online] 2016 [cited 2020 May 27 ];7:45-50
Available from: http://www.picronline.org/article.asp?issn=2229-3485;year=2016;volume=7;issue=1;spage=45;epage=50;aulast=Gupta;type=0